Analyse @AlbertBourla's tweets
Today, we took another step forward in our prostate cancer research, sharing positive topline results from our global trial for metastatic castration-resistant prostate cancer (mCRPC), a disease greatly in need of new solutions: on.pfizer.com/3M3jxMy